Campaigners say that the companies are picking a fight with local legislation to intimidate developing countries into buying medicines at prices set by them.
The companies fixed prices in the European market through a cartel that had a "formal structure and hierarchy," including a regular exchange of sales figures and pricing data.
As investors fret over company accounts, a unit of the US drug giant says it booked $12.4bn in revenue that was never collected. [BBC News] (July 8, 2002)
Legal brief. Allegations include participation in conspiracy to suppress and eliminate competition by fixing the price and allocating the volume of vitamin C manufactured and sold. (May 5, 2000)